Zynerba Pharmaceuticals (ZYNE)

Zynerba Pharmaceuticals Stock Price & Analysis


ZYNE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.71 - $4.36
Previous Close$0.73
Average Volume (3M)438.38K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$59.16M
Total Debt (Recent Filing)$109.69K
P/E Ratio-0.8
Next EarningsNov 14, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.93
Shares Outstanding45,753,079
Standard Deviation0.27
10 Day Avg. Volume373,194
30 Day Avg. Volume438,383
P/B Ratio0.61
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-2.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside870.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Zynerba Pharmaceuticals’s price range in the past 12 months?
Zynerba Pharmaceuticals lowest stock price was $0.71 and its highest was $4.36 in the past 12 months.
    What is Zynerba Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Zynerba Pharmaceuticals’s upcoming earnings report date?
    Zynerba Pharmaceuticals’s upcoming earnings report date is Nov 14, 2022 which is in 38 days.
      How were Zynerba Pharmaceuticals’s earnings last quarter?
      Zynerba Pharmaceuticals released its earnings results on Aug 10, 2022. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.01.
        Is Zynerba Pharmaceuticals overvalued?
        According to Wall Street analysts Zynerba Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Zynerba Pharmaceuticals pay dividends?
          Zynerba Pharmaceuticals does not currently pay dividends.
          What is Zynerba Pharmaceuticals’s EPS estimate?
          Zynerba Pharmaceuticals’s EPS estimate is -$0.23.
            How many shares outstanding does Zynerba Pharmaceuticals have?
            Zynerba Pharmaceuticals has 45,753,080 shares outstanding.
              What happened to Zynerba Pharmaceuticals’s price movement after its last earnings report?
              Zynerba Pharmaceuticals reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went up 4.167%.
                Which hedge fund is a major shareholder of Zynerba Pharmaceuticals?
                Currently, no hedge funds are holding shares in ZYNE


                Zynerba Pharmaceuticals Stock Analysis

                Smart ScoreNeutral
                The Zynerba Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Zynerba Pharmaceuticals

                Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

                Similar Stocks
                Price & Change
                Johnson & Johnson
                Eli Lilly & Co
                Merck & Company
                Bristol Myers

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis